A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

This study is comparing two new treatment approaches against existing standard treatments for adults with multiple myeloma (a cancer of plasma cells in the bone marrow) that has come back or stopped responding to prior therapy. The new drug being tested, linvoseltamab, is an antibody that helps the immune system attack myeloma cells, and it is being tested both on its own and in combination with another drug called carfilzomib. **You may be eligible if...** - You are an adult with multiple myeloma that has relapsed or is no longer responding to treatment - You have received between 1 and 3 prior rounds of treatment, including lenalidomide and at least one other type of drug (a proteasome inhibitor or an anti-CD38 antibody) - You are still reasonably functional in daily activities (ECOG performance score of 2 or less) - Your myeloma is confirmed to be progressing based on standard lab criteria **You may NOT be eligible if...** - You have previously received an immune therapy that specifically targets a protein called BCMA (such as CAR T cells or bispecific T-cell engagers targeting BCMA) - You have plasma cell leukemia, amyloidosis, or a related plasma cell disorder - Your myeloma has spread to the brain or spinal fluid - You have a history of a brain movement disorder or progressive brain infection Talk to your doctor to see if this trial is right for you.